Vosoritide - BioMarin Pharmaceutical

Drug Profile

Vosoritide - BioMarin Pharmaceutical

Alternative Names: BMN-111; Modified C-natriuretic peptide; ProCNP38

Latest Information Update: 01 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioMarin Pharmaceutical
  • Class Cyclic peptides; Natriuretic agents; Natriuretic peptides; Recombinant proteins
  • Mechanism of Action C-type natriuretic peptide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Achondroplasia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Achondroplasia

Most Recent Events

  • 26 Oct 2017 BioMarin Pharmaceutical plans a phase II trial for Achondroplasia (In children, In infants, In neonates) in the first half of 2018
  • 18 Oct 2017 Efficacy data from a phase II trial in Achondroplasia released by BioMarin
  • 03 Mar 2017 Phase-II development is ongoing in Australia, United Kingdom, France and USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top